Envista Holdings stock
NVSTNYSEEnvista Holdings Corp, HealthcareISIN US29415F1049
72Score 72 out of 100, Strong
Price and trend
65 / 100
Price history
+25% in one yearThe chart shows daily closes over 7 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 1.8% below it.
Since October 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 57).
The price is 16% below its 52-week high. Largest decline in 7 years: 71% (March 2022 to April 2025).
Chart figures for advanced users
- SMA 50$24.31
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$25.78
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)57
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$18.95
- The lowest closing price of the last twelve months.
- Resistance$30.26
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Envista Holdings Corp belongs to the Medical (Instruments & Supplies) industry (United States) and, with a market value of $4.06B, is number 25 of 44 companies in its industry on MEQIRI.
- For fiscal 2026, analysts expect on average revenue of $2.87B (up 5.7%) and adjusted earnings per share of $1.54 (up 28.4%).
- MEQIRI Score 72 out of 100 (Strong): rank 105 of 714 in Healthcare, median 53.
Show more
- Our model puts fair value at $35.40, with the price 28% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- High marginNet margin 22% over the last 12 months, Medical (Instruments & Supplies) median 5.9%.Profitability 76
Weaknesses
- Earnings per share fallingDown 42.3% a year since 2022.Growth 68
Its standout strengths are valuation and momentum.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
Valuation
Valuation signal
Modestly undervaluedIn our model the price counts as cheap below $25.28 and expensive above $58.99 (uncertainty high, based on the price swings of the past year).
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $29.31, at 7.8% it would be $44.54.
Valuation metrics
From the cash-flow model alone; the profit includes one-off items, so there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 2 Oct 2026, revenue rose 9.8% on the twelve months before. Revenue has stayed largely stable since 2016.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 55%, operating 8%, net 2%. Last 12 months: net 22%.
Debt & balance sheet
latest quarterModerate debt, and interest is adequately covered.
Earnings
- Next earnings
- 4 Feb 2027in 84 days
- Last reported
- 4 Nov 2026EPS reported $0.40 (expected $0.36)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $1.54+0.7%
- Revenue
- $2.87B−0.1%
- Earnings per share
- $1.67+0.3%
- Revenue
- $2.97B−0.2%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: −2.1%Full-year guidance raised: core growth 3.5% to 4.5%, adjusted EBITDA up 11% to 14%, EPS $1.50 to $1.55, and a tax rate about 2 points lower.
“Our new guidance for the full year 2026 is 3.5% to 4.5% core growth, 11% to 14% adjusted EBITDA growth, adjusted EPS of $1.50 to $1.55 and free cash flow conversion of approximately 100%.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 5 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. One insider sold, $220,000 in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Reis MischaSale
20 Aug 2026, SVP, Strategy & Bus. Dev.
- Shares
- 8,000
- Price
- $27.50
- Value
- $220,000
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Envista Holdings
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 72
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Instruments & Supplies)
The next larger and next smaller companies by market value
- TeleflexTFX $6.2B59
- Merit Medical SystemsMMSI $5.28B61
- ICU MedicalICUI $4.46B54
- Pulse BiosciencesPLSE $4.19B46
- Tecan GroupTECN.SW $3.99B53
- Stevanato GroupSTVN $3.8B49
- SCHOTT Pharma AG & Co. KGaA1SXP.F $3.59B69
- Carl Zeiss MeditecAFX.DE $3.35B64
ETFs that hold Envista Holdings
Held by 11 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| State Street SPDR S&P 400 U.S. Mid Cap UCITS ETF (Acc)SPY4 | 0.12% | 0.30% | €5.27B |
| Invesco Global Buyback Achievers UCITS ETFBBCK | 0.07% | 0.39% | €188.08M |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.06% | 0.30% | €944.34M |
Show 5 more
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.06% | 0.43% | €2.48B |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.04% | 0.45% | €1.53B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.03% | 0.35% | €434.1M |
| UBS MSCI USA Select Factor Mix UCITS ETF USD accUSUE | 0.01% | 0.25% | €175.89M |
| Vanguard ESG Global All Cap UCITS ETF (USD) AccumulatingV3AA | 0.00% | 0.24% | €1.69B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 5 Nov 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.